Articles from SpotitEarly

SpotitEarly, a multi-cancer early detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced that Fierce Healthcare has named it as one of 2026’s “Fierce 15” healthcare companies. The publication’s special report features the most innovative private healthcare companies looking to change the face of the industry.

SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced a strategic partnership with the Fox Chase Cancer Center, which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health.

SpotitEarly, an early cancer detection startup using trained canines and AI to identify cancer odor signatures in breath samples, today announced a research collaboration with the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine. The Hennessy Institute is part of the renowned Hackensack Meridian John Theurer Cancer Center—part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University—and Hackensack University Medical Center.

SpotitEarly, a biotech startup focused on transforming cancer screening by harnessing the power of artificial intelligence and canines to analyze volatile organic compounds (VOCs) in breath samples and detect cancer at its earliest stages, today officially launched in the U.S. market having raised $20.3 million in funding. This funding helps SpotitEarly scale its U.S. presence and strengthen its cancer detection technology, which achieved a 94 percent accuracy rate in a two-year clinical trial including 1400 individuals, published in Nature’s Scientific Reports. The at-home test will be made commercially available in the U.S. in 2026.